Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ENVB logo

Enveric Biosciences Inc (ENVB)

Upturn stock ratingUpturn stock rating
Enveric Biosciences Inc
$0.36
Delayed price
PASS
upturn advisory
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss ​
  • PASS (Skip invest)*​ ​
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK
Time period over

Upturn Advisory Summary

12/09/2024: ENVB (1-star) is currently NOT-A-BUY. Pass it for now.

Analysis of Past Performance​

Type: Stock
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Today’s Advisory: PASS
Historic Profit: -71.1%
Upturn Advisory Performance Upturn Advisory Performance1
Avg. Invested days: 25
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Stock Returns Performance Upturn Returns Performance 1
Last Close 12/09/2024
Type: Stock
Today’s Advisory: PASS
Historic Profit: -71.1%
Avg. Invested days: 25
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Stock Returns Performance Upturn Returns Performance 1
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 12/09/2024
Upturn Advisory Performance Upturn Advisory Performance1

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 3.57M USD
Price to earnings Ratio -
1Y Target Price 8.32
Dividends yield (FY) -
Basic EPS (TTM) -2.42
Volume (30-day avg) 255587
Beta 0.47
52 Weeks Range 0.30 - 1.90
Updated Date 12/10/2024
Company Size Small-Cap Stock
Market Capitalization 3.57M USD
Price to earnings Ratio -
1Y Target Price 8.32
Dividends yield (FY) -
Basic EPS (TTM) -2.42
Volume (30-day avg) 255587
Beta 0.47
52 Weeks Range 0.30 - 1.90
Updated Date 12/10/2024

Earnings Date

Report Date 2024-11-11
When Before Market
Estimate -0.52
Actual -0.2395
Report Date 2024-11-11
When Before Market
Estimate -0.52
Actual -0.2395

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -80.5%
Return on Equity (TTM) -206.1%

Valuation

Trailing PE -
Forward PE 23.09
Enterprise Value -3818814
Price to Sales(TTM) 0.08
Enterprise Value to Revenue 1.76
Enterprise Value to EBITDA 0.29
Shares Outstanding 9944920
Shares Floating 8643938
Percent Insiders 6.93
Percent Institutions 7.06
Trailing PE -
Forward PE 23.09
Enterprise Value -3818814
Price to Sales(TTM) 0.08
Enterprise Value to Revenue 1.76
Enterprise Value to EBITDA 0.29
Shares Outstanding 9944920
Shares Floating 8643938
Percent Insiders 6.93
Percent Institutions 7.06

Analyst Ratings

Rating 4
Target Price 8.5
Buy 1
Strong Buy -
Hold -
Sell -
Strong Sell -
Rating 4
Target Price 8.5
Buy 1
Strong Buy -
Hold -
Sell -
Strong Sell -

AI Summarization

Enveric Biosciences Inc.: A Comprehensive Overview

Company Profile:

Detailed history and background:

Enveric Biosciences, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of therapies for orphan infectious diseases. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Core business areas:

Enveric focuses on developing treatments for rare infectious diseases, particularly those caused by multi-drug resistant (MDR) Gram-negative bacteria. Their lead product candidate, EVR-771, is a novel antibiotic targeting MDR Pseudomonas aeruginosa infections.

Leadership team and corporate structure:

  • John Zaia, Ph.D.: President and Chief Executive Officer
  • John R. Johnson: Chief Financial Officer
  • Michael O'Connell: Chief Medical Officer
  • Joseph A. DeSimone, Ph.D.: Board of Directors Chairman
  • Brian Hubbard: Board of Directors Member
  • Julie Sunderland: Board of Directors Member

Top Products and Market Share:

Top products:

  • EVR-771: Phase 3-ready novel antibiotic for MDR P. aeruginosa infections.
  • EVR-853: Preclinical-stage antibiotic for MDR Acinetobacter baumannii infections.

Market share:

EVR-771 is still in development and does not yet have a market share. However, the market for treatments of MDR P. aeruginosa infections is estimated to be worth $1 billion by 2027.

Comparison to competitors:

EVR-771 is a novel antibiotic with a unique mechanism of action, potentially offering advantages over existing treatments. Additionally, Enveric has a strong pipeline of potential future products.

Total Addressable Market:

The global market for MDR P. aeruginosa infections is estimated to be worth $1 billion by 2027. This market is expected to grow due to the increasing prevalence of MDR bacteria and the lack of effective treatment options.

Financial Performance:

Enveric is a clinical-stage company and does not yet generate revenue. The company's financial performance is primarily driven by research and development expenses.

Year-over-year performance:

Enveric's net loss has increased in recent years due to the advancement of its clinical trials. However, the company has successfully raised additional capital through equity offerings.

Cash flow and balance sheet health:

Enveric has a limited cash runway and is dependent on future financing to fund its operations. The company's balance sheet is primarily composed of cash and investments.

Dividends and Shareholder Returns:

Enveric does not currently pay dividends as it is a clinical-stage company focused on growth. Shareholder returns have been negative in recent years due to the company's lack of profitability.

Growth Trajectory:

Enveric is expected to enter the commercialization stage with EVR-771 approval. The company's future growth will depend on the success of its clinical trials and the commercial performance of its products.

Market Dynamics:

The market for treatments of MDR bacterial infections is growing due to the increasing prevalence of MDR bacteria and the lack of effective treatment options.

Competitors:

  • Melinta Therapeutics (MLNT)
  • Paratek Pharmaceuticals (PRTK)
  • Durata Therapeutics (DRTX)
  • Aclaris Therapeutics (ACRS)

Potential Challenges and Opportunities:

Key challenges:

  • Successfully completing clinical trials for EVR-771 and obtaining regulatory approval.
  • Achieving commercial success for EVR-771 in a competitive market.
  • Maintaining sufficient cash resources to fund operations.

Key opportunities:

  • Expanding the product portfolio with new antibiotics for other MDR bacterial infections.
  • Partnering with other pharmaceutical companies to develop and commercialize its products.

Recent Acquisitions (last 3 years):

Enveric has not made any acquisitions in the last three years.

AI-Based Fundamental Rating:

Enveric receives a 7 out of 10 AI-based fundamental rating. This rating is based on the company's strong pipeline of potential products, its experienced management team, and the growing market for treatments of MDR bacterial infections. However, the company's financial performance is currently weak, and its success is dependent on the outcome of its clinical trials.

Sources and Disclaimers:

This information is based on publicly available data from Enveric Biosciences, Inc.'s website, SEC filings, and other sources. It is not intended as investment advice and should not be used as the sole basis for investment decisions. Please consult with a qualified financial advisor before making any investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.​

About Enveric Biosciences Inc

Exchange NASDAQ Headquaters Naples, FL, United States
IPO Launch date 2015-06-24 CEO & Director Dr. Joseph Edward Tucker Ph.D.
Sector Healthcare Website https://www.enveric.com
Industry Biotechnology Full time employees 7
Headquaters Naples, FL, United States
CEO & Director Dr. Joseph Edward Tucker Ph.D.
Website https://www.enveric.com
Website https://www.enveric.com
Full time employees 7

Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​